Recently, the State Drug Administration passed a priority review and approval procedure to conditionally approve the marketing of tengotinib tablets, a Class 1 innovative drug declared by Pharmaceutical Jiekang Technology Co., Ltd. This drug is used to treat adult patients with advanced, metastatic, or inoperable cholangiocarcinoma who have received systemic treatment and FGFR inhibitor treatment and have fibroblast growth factor receptor 2 fusion or rearrangement. The launch of this drug provides patients with new treatment options.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.